PLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
PLIANT THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$0.90−0.00 (-0.13%)
Close on Oct 19, 2026
- Market cap
- $55.65M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Pliant Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Pliant Therapeutics | Industry median |
|---|---|---|
| Market Cap | $55.65M | $197.05M |
| Enterprise Value | -$102.45M | $106.56M |
| PB Ratio | 0.38 | 2.14 |
| P/TBV Ratio | 0.38 | 2.46 |
Income (trailing twelve months)
| Measure | Pliant Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$97.48M | -$21.44M |
| Net Income | -$92.29M | -$22.46M |
| EBITDA | -$97.48M | -$16.91M |
| EPS (Diluted) | -$1.49 | -$0.83 |
Returns
| Measure | Pliant Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -50.3% | -53.1% |
| Return on Assets (ROA) | -37.7% | -41.0% |
| Return on Capital Employed (ROCE) | -56.2% | -37.8% |
Balance sheet
| Measure | Pliant Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $158.10M | $62.42M |
| Net Cash (Debt) | $158.10M | $15.68M |
| Net Cash Per Share | $2.55 | $0.65 |
| Equity (Book Value) | $146.93M | $48.79M |
| Book Value Per Share | $2.37 | $1.36 |
| Tangible Book Value | $146.93M | $23.06M |
| Working Capital | $146.66M | $75.77M |
Financial position
| Measure | Pliant Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 9.90 | 3.30 |
| Quick Ratio | 9.59 | 2.39 |
| Interest Coverage | -102.50 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Pliant Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$70.90M | -$12.35M |
| Capital Expenditures | $0 | -$1.06M |
| Free Cash Flow | -$70.90M | -$20.28M |
| FCF Per Share | -$1.14 | -$0.41 |
Efficiency
| Measure | Pliant Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.88M | -$732.08K |
| Employee Count | 49 | 73 |
Dividends and yields
| Measure | Pliant Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -165.8% | -21.2% |
| FCF Yield | -127.4% | -7.64% |
| Dividend Yield | 0.00% | 1.83% |
| Shareholder Yield | 0.00% | 0.00% |
| Dividend Per Share | $0.00 | $0.83 |
| Years of Dividend Growth | 0 | 0 |
Shares
| Measure | Pliant Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 61,921,900 | 59,128,900 |
| Shares Change (YoY) | 0.98% | 11.1% |
| Shares Change (QoQ) | 0.01% | 0.54% |
| Float | 53,852,600 | 48,744,500 |
| Shares Held by Insiders | 13.0% | 11.8% |
| Shares Held by Institutions | 77.7% | 59.4% |
Taxes
| Measure | Pliant Therapeutics | Industry median |
|---|---|---|
| Income Tax | $0 | $91.50K |
Scores
| Measure | Pliant Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -6.64 | 0.10 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Pliant Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.